978 Stock Overview
Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Adagene Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.14 |
| 52 Week High | US$3.66 |
| 52 Week Low | US$1.01 |
| Beta | 0.45 |
| 1 Month Change | -10.83% |
| 3 Month Change | -37.79% |
| 1 Year Change | 91.07% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -89.34% |
Recent News & Updates
Recent updates
Shareholder Returns
| 978 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -12.3% | 0.8% | 1.2% |
| 1Y | 91.1% | -24.4% | 2.0% |
Return vs Industry: 978 exceeded the German Biotechs industry which returned -24.4% over the past year.
Return vs Market: 978 exceeded the German Market which returned 2% over the past year.
Price Volatility
| 978 volatility | |
|---|---|
| 978 Average Weekly Movement | 12.4% |
| Biotechs Industry Average Movement | 4.9% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.1% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 978's share price has been volatile over the past 3 months.
Volatility Over Time: 978's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 174 | Peizhi Luo | www.adagene.com |
Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company’s product candidates include ADG106, a human ligand-blocking agonistic anti- CD137 IgG4 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a masked fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase 1b/2 clinical development for the treatment of advanced/metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a v POWERbody, which is in preclinical stage for the treatment off-tumor toxicities, as well as develops anti-CD28 bispecific POWERbody TCEs.
Adagene Inc. Fundamentals Summary
| 978 fundamental statistics | |
|---|---|
| Market cap | €98.43m |
| Earnings (TTM) | -€17.67m |
| Revenue (TTM) | €16.89m |
5.8x
P/S Ratio-5.6x
P/E RatioIs 978 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 978 income statement (TTM) | |
|---|---|
| Revenue | US$18.11m |
| Cost of Revenue | US$0 |
| Gross Profit | US$18.11m |
| Other Expenses | US$37.06m |
| Earnings | -US$18.95m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.43 |
| Gross Margin | 100.00% |
| Net Profit Margin | -104.61% |
| Debt/Equity Ratio | 31.1% |
How did 978 perform over the long term?
See historical performance and comparison